These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30717266)

  • 1. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.
    Gatto EM; Da Prat G; Etcheverry JL; Drelichman G; Cesarini M
    Brain Sci; 2019 Feb; 9(2):. PubMed ID: 30717266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications.
    Zheng W; Fan D
    Front Aging Neurosci; 2022; 14():851135. PubMed ID: 35401150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
    Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
    J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
    Balestrino R; Schapira AHV
    Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease.
    Kinghorn KJ; Asghari AM; Castillo-Quan JI
    Neural Regen Res; 2017 Mar; 12(3):380-384. PubMed ID: 28469644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase and parkinsonism: lessons to learn.
    Marković I; Kresojević N; Kostić VS
    J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial dysfunction associated with glucocerebrosidase deficiency.
    Gegg ME; Schapira AH
    Neurobiol Dis; 2016 Jun; 90():43-50. PubMed ID: 26388395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaucher-Associated Parkinsonism.
    Li Y; Li P; Liang H; Zhao Z; Hashimoto M; Wei J
    Cell Mol Neurobiol; 2015 Aug; 35(6):755-61. PubMed ID: 25820783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases.
    Pchelina SN; Nuzhnyi EP; Emelyanov AK; Boukina TM; Usenko TS; Nikolaev MA; Salogub GN; Yakimovskii AF; Zakharova EY
    Neurosci Lett; 2014 Nov; 583():188-93. PubMed ID: 25265039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology.
    Navarro-Romero A; Fernandez-Gonzalez I; Riera J; Montpeyo M; Albert-Bayo M; Lopez-Royo T; Castillo-Sanchez P; Carnicer-Caceres C; Arranz-Amo JA; Castillo-Ribelles L; Pradas E; Casas J; Vila M; Martinez-Vicente M
    NPJ Parkinsons Dis; 2022 Oct; 8(1):126. PubMed ID: 36202848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocerebrosidase Mutations in Parkinson Disease.
    O'Regan G; deSouza RM; Balestrino R; Schapira AH
    J Parkinsons Dis; 2017; 7(3):411-422. PubMed ID: 28598856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease.
    Nuzhnyi E; Emelyanov A; Boukina T; Usenko T; Yakimovskii A; Zakharova E; Pchelina S
    Mov Disord; 2015 Jun; 30(7):989-91. PubMed ID: 25962734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase and its relevance to Parkinson disease.
    Do J; McKinney C; Sharma P; Sidransky E
    Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.
    Du TT; Wang L; Duan CL; Lu LL; Zhang JL; Gao G; Qiu XB; Wang XM; Yang H
    Autophagy; 2015; 11(10):1803-20. PubMed ID: 26378614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
    Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
    Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.